HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Topical phenytoin versus EUSOL in the treatment of non-malignant chronic leg ulcers.

AbstractOBJECTIVE:
To compare topical diphenylhydantoin (phenytoin) with Edinburgh University solution of lime (EUSOL) in terms of rate of ulcer healing, analgesic and antibacterial properties in non-malignant chronic leg ulcers.
DESIGN:
A prospective randomized controlled study.
SETTING:
Muhimbili National Hospital surgical wards from August 2000 to September 2001.
PATIENTS:
One hundred and two patients with non-malignant chronic leg ulcers of various aetiologies, 50 in the study (phenytoin)group and 52 in the control(EUSOL) group.
INTERVENTIONS:
Study group studied by sprinkling phenytoin powder and the control group with EUSOL, in both groups the ulcers were addressed daily and followed up for 28 days or until they epithelialised or were ready for skin grafting. The data collected included demographic characteristics of patients, aetiology of the ulcers, pus discharge, severity of pain due to the ulcers, bacterial cultures from ulcer swabs, rate of reduction in mean ulcer surface area and outcome of treatment.
RESULTS:
The study enrolled 67 male and 35 female patients over a 14 month period (August to September 2001). Fifty patients formed the study group and 52 formed the controls. The age range was 12-56 years; the majority being in the 27-31 year age group. Major causes of chronic leg ulcers were those infected following trauma (27.5%), chronic non-specific inflammations (21.6%) and infected burn wounds (15.7%). At enrolment, the duration of ulcers ranged from 3-156 weeks and 3-128 weeks in the phenytoin and control groups respectively. Overall, there was significant reduction in pain(p < 0.05) on day seven in the phenytoin group. Furthermore in patients who presented with severe pain, there was a significant reduction in pain in the phenytoin group on the fourteenth day (p < 0.01). Clearance of ulcer discharge was also significant in the phenytoin group on the seventh and fourteenth day of treatment(p < 0.05). The commonest bacteria isolated were pseudomonas aeruginosa (54.9%) and staphylococcus aureus (10.8%). However, bacterial colonization clearance was not statistically significant when the two groups were compared. The rate of formation of healthy granulation tissue was highly significant in the phenytoin group by the fourteenth and twenty first days of treatment (p < 0.001). The phenytoin group showed significant reduction in the mean ulcer surface area on days 7, 14, 21 and 28 (p < 0.05). Chronic ulcers due to animal bites healed fastest followed by those due to trauma.
CONCLUSION:
Phenytoin powder is cheap and easily applied topically on ulcers, effectively relieves pain, clears discharge and enhances formation of granulation tissue thereby promoting healing; reducing morbidity and financial burden enabling its use in resource-poor environments.
AuthorsP M R Carneiro, E T M Nyawawa
JournalEast African medical journal (East Afr Med J) Vol. 80 Issue 3 Pg. 124-9 (Mar 2003) ISSN: 0012-835X [Print] Kenya
PMID12762426 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Bacterial Agents
  • Borates
  • Phenytoin
  • Eusol
  • Sodium Hypochlorite
Topics
  • Administration, Topical
  • Adult
  • Anti-Bacterial Agents (administration & dosage)
  • Borates (administration & dosage)
  • Chronic Disease
  • Colony Count, Microbial
  • Exudates and Transudates (drug effects)
  • Female
  • Humans
  • Leg Ulcer (drug therapy, microbiology, physiopathology)
  • Male
  • Pain Measurement
  • Phenytoin (administration & dosage)
  • Prospective Studies
  • Pseudomonas aeruginosa (growth & development)
  • Sodium Hypochlorite (administration & dosage)
  • Staphylococcus aureus (growth & development)
  • Time
  • Treatment Outcome
  • Wound Healing (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: